Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma). Between desire and reality;Implementation von leitlinien für eine therapie der systemischen sklerose (sklerodermie). Wunsch und wirklichkeit

Zeitschrift fur Rheumatologie

Volumn 69, Issue 4, 2010, Pages 310-317

  Becker, M O ^a   Muller Ladner U ^b   Riemekasten, G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Evidence; Scleroderma; Systemic sclerosis; Therapy; Treatment

Indexed keywords

CLINICAL FEATURE; HUMAN; MEDICAL RESEARCH; PRACTICE GUIDELINE; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; EUROPEAN UNION; GERMANY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC; STANDARDS;

DELIVERY OF HEALTH CARE; EUROPEAN UNION; GERMANY; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; QUALITY ASSURANCE, HEALTH CARE; QUALITY INDICATORS, HEALTH CARE; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC;

EID: 77955588189     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0523-6     Document Type: Review

References (31)

1. Müller-Ladner U (2008) Systemische Sklerose. Internist (Berl) 49:278-285
2. Avouac J, Kowal-Bielecka O, Landewe R et al (2009) European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 68:629-634
3. Kowal-Bielecka O, Landewé R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620-628
4. Schmeiser T, Müller-Ladner U (2009) EULAR-Empfehlungen zur Behandlung der systemischen Sklerose. Z Rheumatol 69:87-92
5. Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962-3970
6. Nihtyanova SI, Brough GM, Black CM, Denton CP (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis. Rheumatology 46:442-445
7. Clements PJ, Furst DE, Wong WK et al (1999) Highdose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194-1203
8. Hunzelmann N, Genth E, Krieg T et al (2009) The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47:1185-1192
9. Steen VD, Medsger TA Jr (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41:1613-1619
10. Morton SJ, Powell RJ (2000) Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology 39:865-869
11. Su TI, Khanna D, Furst DE et al (2009) Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 60:3821-3830
12. Denton CP, Engelhart M, Tvede N et al (2009) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 68:1433-1439
13. Lam GK, Hummers LK, Woods A, Wigley FM (2007) Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34:1636-1637
14. Lafyatis R, Kissin E, York M et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578-583
15. Matteson EL, Shbeeb MI, McCarthy TG et al (1996) Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 39:1132-1137
16. Scherer HU, Burmester GR, Riemekasten G (2006) Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann Rheum Dis 65:1245-1247
17. Levy Y, Amital H, Langevitz P et al (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 50:1005-1007
18. Gabrielli A, Svegliati S, Moroncini G, Avvedimento EV (2007) Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 19:640-645
19. Jacobs MJ, Jörning PJ, Van Rhede van der Kloot EJ et al (1991) Plasmapheresis in Raynaud's phenomenon in systemic sclerosis: a microcirculatory study. Int J Microcirc Clin Exp 10:1-11
20. Knobler RM, French LE, Kim Y et al (2006) A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 54:793-799
21. Laar JM van, Farge D, Tyndall A (2008) Stem cell transplantation: a treatment option for severe systemic sclerosis? Ann Rheum Dis 67 (Suppl 3):iii35-iii38
22. Keysser G, Müller L, Schendel M, Schmoll HJ (2009) Therapeutische Anwendung mesenchymaler Stromazellen bei Autoimmunerkrankungen. Z Rheumatol 68:220, 222-227
23. Brueckner CS, Becker MO, Kroencke T et al (2009) Effect of sildenafil on digital ulcers in systemic sclerosis - analysis from a single centre pilot study. Ann Rheum Dis [Epub ahead of print]
24. Fries R, Shariat K, Wilmowsky H von, Böhm M (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112:2980-2985
25. Rosato E, Borghese F, Pisarri S, Salsano F (2009) The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 28:1379-1384
26. Denton C P, Merkel PA, Furst DE et al (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56:323-333
27. Chung L, Fiorentino DF, Benbarak MJ et al (2009) Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60:584-591
28. Daele PL van, Dik WA, Thio HB et al (2008) Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58:2549-2552
29. Maddali Bongi S, Del Rosso A, Galluccio F et al (2009) Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol 27 (3 Suppl 54):44-50
30. Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62:267-269
31. Cukierman T, Elinav E, Korem M, Chajek-Shaul T (2004) Low dose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 63:1341-1343